New acid blocker may beat standard treatment for stomach bug

NCT ID NCT07537634

Recruiting now Disease control Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer acid-reducing drug (vonoprazan) works better than a standard one (esomeprazole) for clearing H. pylori, a bacteria that can cause stomach ulcers and indigestion. About 80 adults with H. pylori will take one of the two drug combinations for 14 days. Four weeks later, a stool test will check if the infection is gone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vonoprazan or esomeprazole, each combined with amoxicillin and levofloxacin
What this could lead to: If vonoprazan works better, it could offer a more effective option for clearing H. pylori infections, reducing the risk of ulcers and stomach issues.
What could go wrong: This is a small, early-phase 4 trial with only 80 participants, so results may not apply to everyone. Both regimens include antibiotics, which can cause side effects like diarrhea or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSPEPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dyspepsia Helicobacter pylori infectious disease peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSPEPSIA H PYLORI HELICOBACTER PYLORI HELICOBACTER PYLORI INFECTION PEPTIC ULCER DISEASE

Contacts and locations

Locations

Bangabandhu Sheikh Mujib Medical University
NOT_YET_RECRUITING

Dhaka, Bangladesh
Bangabandhu Sheikh Mujib Medical University
RECRUITING

Dhaka, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.